SCHEMBL23994491

SCHEMBL23994491

COc1ncc(-c2cc([C@H]3C[C@@H]3c3ccc(C(F)F)cc3)c3nccn3n2)c(OC)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 11/20 0.34
▸ MTOR P42345 2/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ HCK P08631 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ EPHB4 P54760 1/20 0.33
▸ PRKDC P78527 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33
▸ TP53 P04637 10/20 0.32
▸ SYK P43405 1/20 0.32
▸ MDM4 O15151 2/20 0.32
▸ BRD2 P25440 2/20 0.31
▸ BRD3 Q15059 2/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ CREBBP Q92793 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30182093 1.00 MDM2 (0.34) MDM2MTORPIK3CDABL1EGFR
SCHEMBL25005349 0.92 MTOR (0.33) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993442 0.90 MDM2 (0.33) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993440 0.90 MDM2 (0.33) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23994033 0.89 MTOR (0.35) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993918 0.89 SYK (0.38) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993474 0.89 PPARD (0.34) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993471 0.89 PPARD (0.34) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23994060 0.88 JAK2 (0.35) MDM2MTORPIK3CDABL1EGFR
SCHEMBL23993469 0.88 CYP1A2 (0.38) MDM2MTORSYKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
WO-2021222522-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039553-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E MDM2 2083/4885MTOR 1667/4885PIK3CD 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback